AGEN - צמיחת מכירות משנה לשנה (TTM) Agenus, Inc

Agenus (AGEN) year-over-year product sales volume dynamics for the TTM reflect the impact of aggressive pipeline management, where the current status is 25.70. Growth is driven by patents for unique antibodies aimed at high-margin sales. Despite regulatory challenges, the brand's scientific authority sustains investor interest in innovative cancer therapy methods.
agenusbio.com - פילוחים אנליטיים ומדדי מפתח (AGEN)

To build a high-quality portfolio, I track trailing twelve-month (TTM) revenue dynamics, which measure the pace of business scaling by comparing the current annual window to the same period last year. In the case of Agenus (AGEN), the relative change in TTM revenue compared to the prior year reflects the volatility of licensing fees and royalties from partners, allowing for the timely detection of shifts in the funding cycle for immunotherapy development.